Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Common Stock (Detail Textuals)

Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C, D and F Preferred Stock - Common Stock (Detail Textuals) - USD ($)		1 Months Ended										3 Months Ended		12 Months Ended
	Nov. 01, 2017	Feb. 16, 2018	Jan. 19, 2018	Dec. 28, 2017	Nov. 30, 2017	Oct. 31, 2017	Jan. 31, 2017	Dec. 29, 2016	Oct. 31, 2016	Mar. 31, 2016	Aug. 31, 2015	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Aug. 20, 2015
Equity [Line Items]
Par value of common stock issued (in dollars per share)												$ 0.001		$ 0.001
General and administrative expense												$ 1,226,361	$ 1,288,053
Number of shares issued in conversion												900,000
Warrant exercise price (in dollars per share)															$ 0.25
Preferred stock, shares authorized												20,000,000
Securities purchase agreement \| Emerald Health Sciences Inc
Equity [Line Items]
Par value of common stock issued (in dollars per share)		$ 0.001
Shares issued, price per share (in shares)			15,000,000
Shares issued, price per share (in dollars per share)			$ 0.10
Common stock issued		15,000,000
Number of warrants issued		20,400,000	20,400,000
Warrant exercise price (in dollars per share)		$ 0.10
Term of warrants		5 years
Common stock gross proceeds			$ 1,500,000
Securities purchase agreement \| Emerald Health Sciences Inc \| Accredited investor
Equity [Line Items]
Common stock issued		2,500,000
Number of warrants issued		3,400,000
Warrant exercise price (in dollars per share)		$ 0.10
Term of warrants		5 years
Common stock gross proceeds		$ 1,750,000
Securities purchase agreement \| Emerald Health Sciences Inc \| Bridge Loan
Equity [Line Items]
Aggregate gross proceeds			$ 900,000
Conversion price, per share (in dollars per share)			$ 0.10
Shares converted into common stock			9,000,000
Subsequent financing purchase price, description			The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.
Series B Preferred Stock
Equity [Line Items]
Number of shares converted						777.125					28,335,500	2,833.55		420.325
Number of shares issued in conversion						3,108,500						28,335,500		2,802,167
Conversion price	$ 0.15			$ 0.10	$ 0.10			$ 0.25	$ 0.40	$ 0.80	$ 0.10	$ 0.10		$ 0.25
Shares issued, price per share (in dollars per share)													$ 0.25			$ 0.80
Warrant exercise price (in dollars per share)					0.15
Preferred stock shares convertible into common stock													14,501,500
Series B Preferred Stock \| Series B Preferred stock agreement
Equity [Line Items]
Number of shares converted														1,197.45
Number of shares issued in conversion														5,910,666
Conversion price														$ 0.25
Convertible Series C Preferred Stock
Equity [Line Items]
Number of shares converted														386
Number of shares issued in conversion														1,544,000
Conversion price									0.40					$ 0.25	0.25
Warrant exercise price (in dollars per share)									$ 0.40
Convertible Series D Preferred Stock
Equity [Line Items]
Number of shares converted												200		1,000
Number of shares issued in conversion												2,000,000		4,000,000
Conversion price	$ 0.15			0.10			$ 0.25					$ 0.10		$ 0.25
Shares issued, price per share (in dollars per share)													$ 0.25	0.10
Warrant exercise price (in dollars per share)								$ 0.25							$ 0.25
Preferred stock shares convertible into common stock													2,824,000
Series F Preferred Stock
Equity [Line Items]
Number of shares converted												2,000
Number of shares issued in conversion												20,000,000
Conversion price				0.10	0.15							$ 0.10		$ 0.15
Warrant exercise price (in dollars per share)				$ 0.10	$ 0.15
Series B warrant
Equity [Line Items]
Common stock issued												4,406,250
Intrinsic value of warrant exercises												$ 1,125,291
Common Stock
Equity [Line Items]
Common stock issued for services (in shares)													605,000
Par value of common stock issued (in dollars per share)													$ 0.001
General and administrative expense													$ 187,550
Number of shares converted											1,250
Conversion price											$ 0.80